Formulation development for Yinqiao Qingfei Powder Veterinary Grade API begins with the recognition that the material is not a single chemical entity but a multi-herb extract matrix whose downstream behavior is governed by hygroscopicity, particle size distribution, water solubility, and heat-labile phenolic constituents. Because the powder is supplied as an active ingredient intended for further processing, application-specific blending, granulation, dissolution, and sterilization routes determine whether the finished dosage form meets bioequivalence, stability, and residue requirements. The scenarios below cover only documented production routes in commercial veterinary drug manufacturing and are not intended as regulatory advice.

Does Drinking-Water Solubility Define Field Performance in Closed-House Broiler Respiratory Systems?

Closed-house broiler respiratory syndrome intervention requires a water-soluble powder that remains dispersible in hard water, passes through nipple drinker lines without sedimentation, and avoids triggering biofilm release. The solubility of the multi-herb extract matrix is strongly influenced by total hardness and pH. When total hardness exceeds 180 mg/L CaCO₃ determined by ISO 6059, calcium and magnesium ions reduce the hydration of polysaccharide and phenolic components, forming a sediment layer in header tanks and reducing metering accuracy. The formulation is therefore prepared as a pre-blend containing 60–80 wt% anhydrous glucose monohydrate, 10–20 wt% sodium citrate, and 0.5–1.0 wt% fumed silica, with YQPF extract added at 20–30 wt% of the final water-soluble powder. The dosing rate in field water lines is set at 0.3–0.5 g/L of finished powder, with a stock solution of 10% w/v prepared and injected through a proportional dosing pump at 1:50 to 1:100. During manufacture, the pre-blend is passed through a cone mill fitted with a 180 µm screen to achieve a particle size distribution with D90 ≤ 180 µm measured by laser diffraction under ISO 13320. Production use of an 800 L ribbon blender with spray-bar liquid addition reduces dust and improves homogeneity; batch-to-batch variability in extraction lot density requires revalidation of mixing time when the angle of repose exceeds 38°. Compliance for this dosage form falls under EU Regulation 2019/6 for veterinary medicinal products and manufacturing authorization under Directive 91/412/EEC; in the Chinese domestic route, the finished powder must meet the relevant monograph and GMP requirements of the Chinese Veterinary Pharmacopoeia 2020 Edition. Terminal products include 100 g and 500 g laminated sachets, 1 kg bulk jugs, and in-line stock solutions for proportional medication. The powder is incompatible with strong oxidizing agents such as sodium hypochlorite at residual concentrations above 0.5 ppm, because oxidation of phenolic markers reduces label-claim recovery during stability testing. If the water-soluble powder is stored above 30 °C, hygroscopicity-induced caking is observed; production rooms should therefore maintain a dew point below 10 °C and the transfer system should use vacuum conveying to reduce cross-contamination to other water-soluble veterinary powders.

Swine feed premix incorporation is primarily constrained by carryover control and conditioning temperature. Continuous pelleting lines processing compound feed for nursery and grower pigs require the API to be introduced through a registered premix or intermediate pre-blend rather than direct addition to the mixer. Under EU Regulation 2019/4, manufacture of medicated feed and intermediate products requires HACCP-based carryover controls, and sampling plans must be established following ISO 6498. A typical formulation converts the extract into a 10% w/w pre-blend by dispersing YQPF powder in calcium carbonate or corn cob meal; the pre-blend is then dosed at 5.0–10.0 kg per tonne of finished feed, corresponding to 0.5–1.0 kg YQPF extract per tonne. Batch mixing is carried out in a 500 kg horizontal twin-shaft mixer with a 1:5 pre-blend sequence and a coefficient of variation for active marker recovery of less than 5%. Steam conditioning should not exceed 75 °C for longer than 30 seconds because loss of chlorogenic acid and forsythoside A accelerates above this thermal threshold; published data for this specific extract in pelleted grower-finisher feed under commercial conditioner residence time is limited, so production trials should include marker degradation sampling at 0, 15, 30, and 45 minutes of conditioning. Terminal products are pelleted and crumble feeds, medicated premixes in 5 kg and 20 kg bags, and top-dress meal formulations for sows. The fine herbal matrix contains particles below 10 µm, which become airborne during open transfer, so dust extraction and wet washing procedures are required at the transfer station.

Granulation Endpoints, Moisture Migration, and Tablet Compression Limits in Low-Dust Oral Dosage Forms

Granulated oral preparations are manufactured where dust generation during farm-level top dressing is unacceptable. In a high-shear granulator with a 300 L bowl and 10-bar spray nozzle, the YQPF extract is dry-blended with 25–40 wt% mannitol, 40–55 wt% microcrystalline cellulose PH102, 3–5 wt% povidone K30, and 2–4 wt% crospovidone; the final active loading is limited to 40 wt% because excessive extract raises binder consumption and produces bimodal agglomerates. Wet granulation uses 60–70% v/v ethanol as the binding solvent, added at 12–14% w/w of total batch; the endpoint is judged by torque rise from 18 N·m to 32 N·m on a 300 L high-shear granulator. After wet massing, the material is discharged through a 4 mm square mesh and dried in a fluid-bed dryer at 45–55 °C until loss on drying reaches 2–4% by Chinese Pharmacopoeia 0832. In commercial batches, moisture above 4% causes adhesion during sachet filling, while moisture below 2% increases electrostatic dust and granule attrition. When the dried granulate is intended for tablet compression, it is milled through a 1.0 mm screen, blended with 1–2 wt% magnesium stearate, and compressed on a rotary tablet press at 8–12 kN compaction force; tablet friability is held below 1% measured by European Pharmacopoeia 2.9.7, and hardness is maintained between 50 N and 80 N. Compliance follows EU Regulation 2019/6, Directive 91/412/EEC, and VICH GL3 stability protocols; microbiological quality is tested by Chinese Pharmacopoeia 1105 for non-sterile products, with total aerobic microbial count controlled to 10³ CFU/g and bile-tolerant Gram-negative bacteria absent in 1 g. Terminal products include 50 g and 200 g sachets, 1 kg jars, pre-dosed oral top-dress granules for swine and calves, and 500 mg compressed tablets.

Liquid oral delivery in milk-fed calves presents a suspension rather than a true solution because the extract matrix contains water-insoluble polysaccharide and tannin-polysaccharide complexes. The formulation is processed as a stabilized suspension with 20–50 g/L YQPF extract, 10–15% v/v propylene glycol, 0.5–1.0% w/v xanthan gum, 0.1–0.2% w/v potassium sorbate, and citric acid/sodium citrate to pH 5.5–6.5. The finished product is manufactured in a 500 L vacuum emulsifying mixer equipped with a rotor-stator homogenizer; the gum is hydrated separately for 30 minutes before addition to avoid fish-eye hydration defects. After homogenization at 3,000 rpm for 15 minutes, the suspension is filled into 500 mL, 1 L, and 5 L HDPE bottles with induction-sealed caps. Compliance is assessed under EU Regulation 2019/6 as a veterinary medicinal product and under non-sterile microbial quality criteria using European Pharmacopoeia 5.1.4. Terminal products are oral drench, liquid premix for milk replacer, and bucket dosing systems used in calf barns. The suspension is not compatible with high-ionic-strength electrolyte feeds above 15% solids because ionic shielding collapses the xanthan network and causes rapid sedimentation.

What Prevents Crude Herbal Powder From Meeting Injectable Requirements?

Injectable dosage forms require the elimination of endotoxins, particulate matter, and high-molecular-weight polysaccharides. Crude YQPF powder cannot be formulated directly for injection because the bacterial endotoxin load of non-de-pyrogenated plant material typically exceeds the acceptance threshold of 0.5 EU/mg specified in European Pharmacopoeia 2.6.14. Where a purified aqueous extract fraction is developed for injectable use, it is concentrated to 10–25 mg/mL in Water for Injection, adjusted to pH 5.5–6.5 with sodium hydroxide or hydrochloric acid, and made isotonic with 0.9% w/v sodium chloride. The manufacturing route includes cold-water extraction at 2–8 °C, continuous flow centrifugation at 15,000 × g, filtration through 0.45 µm followed by 0.22 µm polyethersulfone membrane, and aseptic filling under Grade A conditions. Moist heat terminal sterilization is not recommended because high temperatures accelerate hydrolysis of phenolic glycosides; aseptic processing remains the preferred route. The solution is incompatible with amine-based pH modifiers such as tromethamine, which produces insoluble complexes with phenolic acid markers. Published data for this specific extract in injectable form is limited, so pilot-scale regulatory stability data must be generated before any commercial dossier submission. Compliance for injectable veterinary medicines under EU Regulation 2019/6 requires full safety, efficacy, and residue documentation. Terminal products are 10 mL and 20 mL amber ampoules or vials, filled under nitrogen to minimize oxidative discoloration.

Compounded hard capsules containing YQPF extract are produced where national prescribing routes permit herbal veterinary preparations in companion and equine patients, but no harmonized EU or FDA marketing authorization for this specific extract exists. Published data for this specific configuration is limited. The formulation uses 200–400 mg YQPF extract per size 0 or 1 hard gelatin capsule, with 45–65 wt% microcrystalline cellulose PH102, 1–2 wt% magnesium stearate, and 0.5–1.0 wt% colloidal silicon dioxide. Because the extract is hygroscopic at relative humidity above 60%, the processing area must maintain 35–45% RH, and filling is preceded by pre-drying at 45 °C for 2 hours. The blend is produced by roller compaction to prevent segregation and then filled on an intermittent-motion capsule machine at 40,000–90,000 capsules/hour. Weight uniformity is tested per Chinese Pharmacopoeia 0941 or European Pharmacopoeia 2.9.5. Microbiological limits follow Chinese Pharmacopoeia 1105; for export markets that recognize the Chinese Veterinary Pharmacopoeia, pesticide residue screening is performed according to Chinese Pharmacopoeia 2341 and heavy metal testing according to Chinese Pharmacopoeia 0821. Terminal products are blister packs and HDPE bottles. The formulation is incompatible with alkaline fillers such as magnesium oxide, which raises blend pH above 8 and destabilizes phenolic marker compounds.